➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Harvard Business School
Mallinckrodt
Medtronic
Johnson and Johnson

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Epelsiban


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Epelsiban?

Epelsiban is an investigational drug.

There have been 4 clinical trials for Epelsiban. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2016.

The most common disease conditions in clinical trials are Adenomyosis and [disabled in preview]. The leading clinical trial sponsors are GlaxoSmithKline and [disabled in preview].

There are fourteen US patents protecting this investigational drug and ninety-one international patents.

Recent Clinical Trials for Epelsiban
TitleSponsorPhase
Placebo-controlled Proof of Concept Study of Epelsiban in Women With AdenomyosisGlaxoSmithKlinePhase 2
Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women VolunteersGlaxoSmithKlinePhase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female VolunteersGlaxoSmithKlinePhase 1

See all Epelsiban clinical trials

Clinical Trial Summary for Epelsiban

Top disease conditions for Epelsiban
Top clinical trial sponsors for Epelsiban

See all Epelsiban clinical trials

US Patents for Epelsiban

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Epelsiban   Get Started Free Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies Ferring B.V. (Hoofddorp, NL)   Get Started Free
Epelsiban   Get Started Free Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof Merck Serono S.A. (Coinsins, CH)   Get Started Free
Epelsiban   Get Started Free Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof ObsEva S.A. (Plan-les-Ouates, CH)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Colorcon
McKesson
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.